Publication Name	World Journal of Gastroenterology
Manuscript ID	34971
Country	Iran

Received	2017-06-07 00:39
Peer-Review Started	2017-06-08 01:08
To Make the First Decision	2017-07-13 05:02
Return for Revision	2017-07-17 11:55
Revised	2017-09-14 03:49
Second Decision	2017-09-15 00:07
Accepted by Journal Editor-in-Chief	2017-09-16 02:36
Accepted by Executive Editor-in-Chief	2017-09-19 21:01
Articles in Press	2017-09-19 21:01
Publication Fee Transferred
Edit the Manuscript by Language Editor	2017-10-30 20:59
Typeset the Manuscript	2017-11-06 04:41
Publish the Manuscript Online	2017-11-12 06:39

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Editorial
Article Title	Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Ahad Eshraghian
ORCID	Author(s) ORCID Number Ahad Eshraghian http://orcid.org/0000-0003-0751-5712
Funding Agency and Grant Number
Corresponding Author	Ahad Eshraghian, MD, Gastroenterohepatology Research Center, Shiraz University of Medical Sciences, Shiraz 71937-11351, Iran. eshraghiana@yahoo.com
Key Words	Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Vitamin E; Pioglitazone; Pharmacological therapy; Obeticholic acid
Core Tip	Non- alcoholic fatty liver disease (NAFLD) is an increasing liver disease worldwide. However, most of patients are treated with life style modification including weight loss and dietary regimen. Pharmacologic therapy may be indicated in a group of patients with non-alcoholic steatohepatitis. Here in, the current and emerging medications for treatment of NAFLD was reviewed briefly with regard of their beneficial effects on histological outcomes.
Publish Date	2017-11-12 06:39
Citation	Eshraghian A. Current and emerging pharmacological therapy for non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(42): 7495-7504
URL	http://www.wjgnet.com/1007-9327/full/v23/i42/7495.htm
DOI	http://dx.doi.org/10.3748/wjg.v23.i42.7495

Full Article (PDF)	WJG-23-7495.pdf
Full Article (Word)	WJG-23-7495.doc
Manuscript File	34971-Review.docx
Answering Reviewers	34971-Answering reviewers.pdf
Audio Core Tip	34971-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	34971-Conflict-of-interest statement.pdf
Copyright License Agreement	34971-Copyright assignment.pdf
Peer-review Report	34971-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	34971-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	34971-Scientific misconduct check.pdf
Scientific Editor Work List	34971-Scientific editor work list.pdf